Back to Search
Start Over
High-dose tramadol conversion to buprenorphine-naloxone.
- Source :
-
Journal of opioid management [J Opioid Manag] 2023 Mar-Apr; Vol. 19 (2), pp. 187-190. - Publication Year :
- 2023
-
Abstract
- Buprenorphine-naloxone is a combination medication of an opioid partial agonist and opioid antagonist that is proven to be effective in outpatient management of opioid use disorder (OUD). Tramadol is a centrally acting analgesic. This commonly used pain medication inhibits serotonin and noradrenaline reuptake by acting as a selective agonist on opioid µ receptors. Transition and tapering high-dose tramadol to buprenorphine-naloxone is not well described in the literature. We report a case of a patient who was taking 1,000-1,250 mg of tramadol daily upon presentation to the clinic. She was originally prescribed 150 mg daily with escalation in dose and frequency over a 10-year period. The patient was converted to bupren-orphine-naloxone and has been successful in treatment of OUD for 1 year.
Details
- Language :
- English
- ISSN :
- 1551-7489
- Volume :
- 19
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of opioid management
- Publication Type :
- Academic Journal
- Accession number :
- 37270427
- Full Text :
- https://doi.org/10.5055/jom.2023.0774